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Highlights 
 TMEV VP1 localises to the perinuclear region and cytoplasm of infected cells 
 TMEV VP1 and Hsp90 colocalise in the perinuclear region and cytoplasm  
 TMEV VP1 did not localise to the nucleus during infection  
 A typical NLS was absent from the TMEV VP1 sequence 
 TMEV VP1 localises in a similar manner to FMDV and EV71 VP1 
 
Abstract 
The VP1 subunit of the picornavirus capsid is the major antigenic determinant and mediates 
host cell attachment and virus entry. To investigate the localisation of Theiler's murine 
encephalomyelitis virus (TMEV) VP1 during infection, a bioinformatics approach was used 
to predict a surface-exposed, linear epitope region of the protein for subsequent expression 
and purification. This region, comprising the N-terminal 112 amino acids of the protein, was 
then used for rabbit immunisation, and the resultant polyclonal antibodies were able to 
recognise full length VP1 in infected cell lysates by Western blot. Following optimisation, 
the antibodies were used to investigate the localisation of VP1 in relation to Hsp90 in 
infected cells by indirect immunofluorescence and confocal microscopy. At 5 hours post 
infection, VP1 was distributed diffusely in the cytoplasm with strong perinuclear staining but 
was absent from the nucleus of all cells analysed. Dual-label immunofluorescence using anti-
TMEV VP1 and anti-Hsp90 antibodies indicated that the distribution of both proteins 
colocalised in the cytoplasm and perinuclear region of infected cells. This is the first report 
describing the localisation of TMEV VP1 in infected cells, and the antibodies produced 
provide a valuable tool for investigating the poorly understood mechanisms underlying the 
early steps of picornavirus assembly. 
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1. Introduction 
Picornaviruses are a diverse family of small non-enveloped RNA viruses that includes 
various pathogens of significant clinical and economic importance. Notable human pathogens 
include poliovirus (PV), human rhinovirus (HRV), Coxsackievirus A and B (CVA; CVB), 
enterovirus 71 (EV71) and hepatitis A virus (HAV) (Hagan et al., 2015; Rotbart and Hayden, 
2000). Animal pathogens of high economic importance include foot-and-mouth disease virus 
(FMDV) and swine vesicular disease virus (SVDV) (Brito et al., 2015; Mansour et al., 2015).  
The picornavirus capsid is a non-enveloped icosahedral capsid with pseudo-T = 3 symmetry 
and is approximately 30 nm in diameter. The capsid consists of 60 capsomers each of which 
contains three subunits, namely VP1, VP2 and VP3. A fourth capsid protein, VP4, is found 
on the internal side of the capsid (Bedard and Semler, 2004). Picornavirus capsids exemplify 
macromolecule assembly through the consecutive oligomerisation of different protein 
complexes (Fig. 1). Following the cleavage of the precursor P1, the subunits assemble into 
protomer structures, each comprising a single copy of the VP0, VP1 and VP3 subunits. The 
pentamer structures are subsequently formed through the interaction of five protomer 
structures. Formation of 80S empty procapsids then occurs following the assembly of 12 
pentamer structures. Alternatively 12 pentamers assemble around the mRNA genome to 
constitute the 150S provirion, and cleavage of the VP0 precursor yields mature infectious 
virus particles (Jiang et al., 2014).  
The most external and accessible surface protein of the capsid is VP1. The general structure 
of the protein is wedge shaped and consists of eight stranded β-barrels, with connecting loops 
between the barrels and the N and C termini of the protein (Rueckert, 1996). VP1 has been 
reported to play a role in host cell attachment, and is considered the most immunodominant 
of the four capsid proteins (Edlmayr et al., 2011; Meloen Briaire et al., 1983; Rossmann et 
al., 1985). There have been several investigations into the identification of immunogenic 
regions within this protein.  In FMDV, the VP1 capsid protein has been reported to contain 
the highest number of neutralisation sites, particularly within the βG-βH loop region (Collen 
et al., 1991). Varrasso et al., (2001) identified neutralisation sites located within the N and C 
termini as well as the βE-βF and βG-βH loops of Equine Rhinitis Virus (ERAV) VP1, with 
strong antibody recognition against the N-terminus. Similarly, major VP1 neutralisation sites 
have been reported for TMEV (Cameron et al., 2001; Luo et al., 1992) and the enteroviruses 
(Mateu, 1995; Oberste et al., 1999; Wu et al., 2001) with key neutralising determinants 
located in the N-terminal region of VP1 (Bobek et al., 2010; Tan and Cardosa, 2007) . 
Since picornavirus genomes have limited coding capacity, these viruses are dependent on a 
range of host cellular proteins and pathways to mediate viral entry, replication and assembly. 
While it has been established that pentamers self-assemble into intact empty capsids in vitro 
in a process mediated by protein-protein interactions with no apparent requirement for other 
viral or cellular factors (Li et al., 2012; Rombaut et al., 1991), the steps between P1 to 
pentamer assembly are complex, and appear to involve multiple viral and cellular 
components. Significantly, it has been established that chaperones in the heat shock protein 
family, for example Hsp90 and Hsp70, are crucial for enterovirus replication as indicated by 
an association of these chaperones with the capsid P1 precursor (Geller et al., 2007; Macejak 
and Sarnow, 1992). While strong evidence links the involvement of Hsp90 in P1 processing, 
it has also been reported that Hsp90 promotes the formation of pentamers from 5S protomers 
during FMDV infection (as reviewed by Jiang et al., 2014).  
To date, most studies investigating picornavirus replication and assembly have been carried 
out using picornaviruses such as PV, HAV and FMDV. Very few describe the localisation of 
picornavirus capsid subunits in cells at the early stages of virus assembly, which remains a 
poorly understood process in the virus life cycle. Theiler's murine encephalomyelitis virus 
(TMEV) is a naturally occurring murine Cardiovirus infecting the central nervous system of 
mice causing demyelination (Lipton, 1975). Several strains of the virus have been identified 
with the GDVII and FA strains being highly neurovirulent and causing acute fatal 
encephalitis in mice. The BeAn and DA strains are less virulent inducing a chronic 
demyelinating condition, and these have been extensively studied as a model for investigating 
the pathogenesis of multiple sclerosis (reviewed by Oleszak et al., 2004). Furthermore, the 
capsid structure of the TMEV DA strain has been determined at atomic resolution using X-
ray crystallography providing a template on which other strains can be modelled (Grant et al., 
1992). Our previous studies have reported that the TMEV GDVII 2C protein localises to the 
Golgi apparatus and endoplasmic reticulum (ER) both during infection, and when expressed 
alone in cells (Jauka et al., 2010; Murray et al., 2009).  In addition, we have reported that  
TMEV infection results in a redistribution of Hsp90 into the replication complex where it 
overlaps with viral replication protein 2C, and that inhibition of Hsp90 by geldanamycin and 
novobiocin supresses the cytopathic effect of the virus suggesting an important role for this  
protein in the virus life cycle (Mutsvunguma et al., 2011). To extend these studies and further 
investigate virus-host interactions during infection, we used a bioinformatics approach to 
analyse the nucleotide sequence of the VP1 capsid subunit and predict a potential antigenic 
region. The peptide consisting of amino acids 1-112 in frame with a 6x histidine tag was 
successfully expressed in Escherichia coli cells, solubilised in the presence of N-
Lauroylsarcosine and purified for subsequent immunisation of rabbits. The antibodies were 
used to investigate the localisation of VP1 at 5 hours post infection (hpi) and determine the 
distribution of VP1 relative to Hsp90. 
 
2. Materials and Methods 
2.1 Homology modelling of the TMEV GDVII protomer complex 
2.1.1 Sequence retrieval, alignment and template selection 
The protein sequences, corresponding to the four subunits of the TMEV GDVII protomer 
were retrieved from the GenBank database (NCBI VP1-VP4: NP_740427.1, NP_740425.1, 
NP_740426.1, NP_740424.1) in FASTA format. The sequences were individually submitted 
to HHpred (Soding et al., 2005) for the identification of homologous protein structures for 
each subunit. As the study aimed to model the full TMEV GDVII protomer complex, only 
full protomer structures which contained template chains for all four protomer subunits were 
selected as possible templates. Initially, ten structures were selected as possible templates 
(supplementary table S1). The structural alignment program PROMALS3D (Pei et al., 2008) 
was then used to align the target sequences of each respective GDVII protomer subunit to ten 
structural sequences corresponding to the subunits of selected protomer templates. To ensure 
that the subunit-subunit interfaces were modelled correctly, each protomer template was 
submitted to the Protein Interactions Calculator (PIC) (Tina et al., 2007) for the identification 
of residues involved in inter-protein interactions. As each of the four subunits interacts with 
three other subunits, a total of 12 interfaces were examined. The interacting residues, 
predicted for each subunit-subunit interface, were then mapped to the respective multiple 
sequence alignments using in-house scripting. To assess the conservation of interface 
residues against the target sequences, the resulting alignments were visualised in Jalview 
(Waterhouse et al., 2009). An example of this analysis is shown for the VP1 subunit in 
supplementary Fig. S1. Subsequent to the observation that predicted interacting residues were 
highly conserved across the ten structures the final template selection was based on the 
following criteria: i) highest average sequence identity to the target protomer as calculated 
across all four subunit proteins, ii) template resolution and iii) the sequence identity to the 
VP1 subunit (supplementary table S1). The crystal structures of TMEV DA (PDB ID: 1TME) 
and HEV-D68 (PDB ID: 4WM8) were selected as templates for the modelling of the TMEV 
GDVII protomer (supplementary table S2).  
2.1.2 Model building and validation 
Homology models of the full TMEV GDVII protomer complex were calculated using 
MODELLER 9v15 (Sali and Blundell, 1993), set to generate 100 unique models through very 
slow refinement. Given that the TMEV DA structure (PDB ID: 1TME) had high sequence 
identity to the target; an initial model set based only on this template was constructed. In an 
attempt to improve the quality of the models, a second model set based on a combination of 
TMEV DA with the higher resolution structure of HEV-D68 (PDB ID: 4WM8) was 
constructed. The models were initially evaluated according to the normalized DOPE-Z score 
(supplementary table S3). To validate the models’ subunit interfaces the three best scoring 
models from each set were submitted to PIC followed by the mapping of predicted interacting 
residues to multiple sequence alignments. The models were also visualised in PyMOL 
(Schrodinger, 2010) for the identification of any geometric discrepancies. The top scoring 
model was additionally evaluated using PROSA (Wiederstein and Sippl, 2007). 
2.2 Prediction of linear epitope regions on the surface of TMEV GDVII VP1 
Linear epitope regions within TMEV GDVII VP1 were predicted using the webservers EliPro 
(Ponomarenko et al., 2008) and BepiPred (Larsen et al., 2006). The predicted VP1 epitopes 
were mapped to the homology model of the TMEV GDVII protomer to validate surface 
accessibility of these regions when the VP1 subunit is in an assembled protomer complex. 
The mapping and structural analysis was performed in PyMOL (Schrodinger, 2010). To 
investigate the epitope regions which were more likely to be soluble the GDVII VP1 
sequence was submitted to Protscale (Gasteiger et al., 2005) for the prediction of 
hydrophobic and hydrophilic regions based on the Kyte and Doolittle method (Kyte and 
Doolittle, 1982). 
 
 
2.3 Prediction of nuclear localisation signals and multiple sequence alignment of the C-
terminus of VP1 
The VP1 sequences of TMEV GDVII (NCBI: NP_740427), CVB3 (GenBank accession: 
U57056), EV71 (GenBank accession: HQ882182) and FMDV (GenBank accession: 
CAA00045) were retrieved from the GenBank database. The sequences were individually 
submitted to NucPred (Brameier et al., 2007) and SeqNLS (Lin and Hu, 2013) for the 
prediction of a nuclear localisation site. For identification of amino acid mutations the 
sequences were aligned using Promals3D (Pei et al., 2008) and visualised in Jalview 
(Waterhouse et al., 2009).  
2.4 Plasmids 
TMEV VP1 (1-112) was expressed in the E. coli strain JM109 from plasmid pCRTVP1. To 
create this plasmid, nucleotides 1-336 of the TMEV VP1 coding sequence were PCR-
amplified from the TMEV GDVII cDNA, using the KAPA Taq ReadyMix kit (KAPA 
Biosystems, Cape Town, South Africa) and gene-specific oligonucleotide primers. The PCR 
product was ligated into plasmid pQE-80L (Qiagen, Mannheim, Germany) by restriction with 
BamHI and SalI. To confirm the presence of the insert and correct open reading frame, 
plasmid pCRTVP1 was sequenced by Inqaba Biotechnical Industries (Pty) Ltd., Pretoria 
South Africa. 
2.5 Protein expression, SDS-PAGE and Western blotting 
E. coli cells transformed with pCRTVP1 and pQE-80L were cultured in Luria broth (LB) 
supplemented with 100 µg/ml ampicillin at 37°C overnight. Cultures were induced with 1 
mM Isopropyl β-D-1-thiogalactopyranoside (IPTG) for 4 hours and duplicate samples 
collected each hour. The cells were harvested by centrifugation at 11800 x g and pellets were 
resuspended to equivalent density in phosphate buffered saline [PBS; 137 mM NaCl, 2.7 mM 
KCl, 10 mM Na2HPO4, 2 mM KH2PO4 (pH 7.4)]. Proteins were denatured in 2X loading 
buffer and resolved by 12% SDS-PAGE before being transferred onto nitrocellulose 
membrane for Western blotting using Anti-His6 (2) antibodies. Detection was performed 
using the BM Chemiluminescence Western Blotting Kit (Roche, Mannheim, Germany) 
according to the manufacturer’s instructions. Proteins were visualised using the ChemiDoc 
Molecular Imager XRS + (Bio-Rad, USA), and images were analysed using the Image Lab 
TM software, version 5.1. 
2.6 Purification of VP1 (1-112) 
An 80 ml overnight culture transformed with pCRTVP1 was induced and cells harvested by 
centrifugation at 6000 x g. Prior to sonication for 1 min on ice, the pellets were resuspended 
in ice cold 1xLEW buffer [50 mM Na2PO4, 300 mM NaCl, (pH 8.0)] supplemented with 30 
mM imidazole and 7.5% N-Lauroylsarcosine (sarcosyl). Samples were clarified by 
centrifugation to obtain the supernatants which were pooled and purified using Protino Ni-
IDA packed columns (Machery-Nagel). The peptide was eluted with 1xElution buffer [50 
mM Na2PO4, 300 mM NaCl, 250 mM imidazole, (pH 8.0)]. The protein concentrations of 
eluted fractions were determined by Bradford’s assay. Purified protein was concentrated in 
VIVASPIN 4 columns (Satorius Stedim Biotech, South Africa). A total of 1.2 mg purified 
TMEV VP1 (1-112) was used for rabbit immunisation.  
 
2.7 Antibodies 
Anti-His6 (2) (1:3000) recognising the 6x histidine tag on pQE80-L were purchased from 
Roche (Mannheim, Germany). Polyclonal antibodies against TMEV VP1 (1-112) were 
generated in rabbits by D. Bellstedt (University of Stellenbosch, South Africa). Rabbit 
antibodies against TMEV GDVII non-structural protein 2C were used at a concentration 
1:1000 for indirect immunofluorescence (Jauka et al., 2010). Antibodies recognising Hsp90α 
and β isoforms (SC-13119) were from Santa Cruz Biotech, Santa Cruz, USA and used at 
1:100.  
2.8 Cells, viruses and infections 
BHK-21 cells (kindly provided by M. Ryan, University of St Andrews, UK) were cultured in 
buffered Dulbecco’s modified Eagle Medium (DMEM, Lonza Group Ltd, Basel, 
Switzerland) supplemented with 10% heat-inactivated foetal calf serum, 100 U penicillin 
ml−1, 10 mg streptomycin ml−1 and 25 μg fungizone ml−1 at 37°C with 10% CO2. TMEV 
strain GDVII was used to infect cells in all experiments. Virus stocks were prepared and 
titred using BHK-21 cells as described previously (Murray et al., 2009). For indirect 
immunofluorescence experiments, cells were infected at a multiplicity of infection (M.O.I) of 
approximately 3. 
 
2.9 Preparation of infected cell lysate for Western blot 
For the Western blot of infected lysates, cells were collected by centrifugation at 1000 x g 
and resuspended in 200 µl PBS. Total proteins were denatured and resolved by 12% SDS–
PAGE before transfer onto nitrocellulose membrane for Western blotting using anti-TMEV 
VP1 antibodies. The BM Chemiluminescence Western Blotting kit (Roche, Mannheim, 
Germany) was used to detect viral protein according to manufacturers’ instructions. 
2.10 Indirect immunofluorescence and confocal microscopy 
Cells grown on sterile 13 mm glass coverslips to 100% confluency in six-well plates 
containing complete medium were washed twice with serum-free DMEM before the addition 
of 1 ml of TMEV GDVII virus stock and 1 ml serum-free DMEM. Following incubation for 
1 hour at 25 ̊ C, cells were rinsed with PBS and 5 ml DMEM was added. The cells were 
incubated at 37º C, and lysates were prepared at 5 hours post infection (hpi). Control cells 
were mock-infected with serum-free DMEM. At 5 hpi, cells were collected by trypsinisation 
and washed with PBS before fixation with 4% paraformaldehyde for 20 min at room 
temperature (RT). For staining, cells were permeabilised in PB (10% sucrose, 1% Triton X-
100 in PBS), blocked in PB containing 2% BSA for 30 min at RT and incubated with primary 
antibodies for 1 hour with shaking. Cells were washed with PBS containing 0.1% Tween-20, 
and incubated with species-specific Alexa Fluor 488-conjugated and/or Alexa Fluor 546-
conjugated secondary antibodies for 30 min, followed by three washes. To stain the nucleus, 
4’,6-diamino-2-phenylindole dihydrochloride (DAPI, Sigma, St Louis, USA) was added at a 
concentration of 0.8 μg/ml in the second wash step. Cells were mounted using 
Dakofluorescence mounting medium (Dako Inc, CA, USA) and stored at RT. The 
helium/neon and argon lasers at wavelengths 405, 488 and 543 nm were used to excite DAPI, 
Alexa-fluor 488 and Alexa-fluor 546 respectively. Images were captured using the Zeiss 
LSM 510-Meta laser scanning confocal microscope and analysed using Zen software (blue 
edition, Zeiss, Germany). In order to acquire a representative image for each experiment, 
over 100 cells were viewed at 63 x magnification. Colocalisation analysis was performed on 
five randomly selected cells. Immunofluorescence experiments were performed in triplicate.  
 
3. Results 
3.1 Homology modelling of the TMEV GDVII protomer complex 
The TMEV GDVII VP1 protein exists in complex with 3 other heterogenic subunits VP2-
VP4. To distinguish predicted VP1 epitopes which remain exposed in the protomer complex 
from those which reside in an inter-subunit interface the 3D structure of the full TMEV 
GDVII protomer was calculated based on the known structures of homologous viral 
protomers (supplementary table S2). Initially ten crystal structures of homologous protomer 
structures were identified as possible templates (supplementary table S1). As explained in the 
Methodology section, out of ten two structures were chosen as final templates for model 
building (supplementary table S2). The structure 1TME was selected as a result of its high 
sequence identity to the GDVII protomer. The second structure 4WM8 was selected due to its 
higher resolution and was to be used in combination with 1TME in an attempt to improve 
model quality. 
A primary aim of the study was to predict epitope regions within the VP1 subunit. Therefore, 
irrespective of the low sequence identity of 4WM8 to the full GDVII protomer, the template 
was still used as the VP1 subunits were 50% identical to each with the interface residues 
conserved. We constructed two different sets of models based on i) the lower resolution but 
high sequence identity template 1TME and ii) a combination of 1TME with a higher 
resolution template 4WM8. It must be noted that 1TME and 4WM8 were in the same 
conformation. The initial evaluation of the normalised DOPE-Z scores revealed a substantial 
increase in the quality of the models generated by a combination of 1TME and 4WM8 
(supplementary table S3). For additional validation, the top three models of the GDVII 
protomer from each set were submitted to PIC for the prediction of interacting interface 
residues. The interacting residues were mapped to MSAs of the respective subunits of the six 
GDVII models. The MSAs also included the template sequences of 1TME and 4WM8. The 
interacting residues within all subunit-subunit interfaces predicted for both sets of GDVII 
models were completely conserved in the alignments. An example of this validation is shown 
in supplementary Fig. S2.  The structural investigation of the models using PyMOL revealed 
no obvious geometric discrepancies. Since there was no improvement in the interface 
residues based on the use of the single but higher identity template 1TME, the best scoring 
model was selected based on the combination of 1TME and 4WM8 for epitope prediction.  
The program PROSA was used to further investigate the overall quality of the selected 
model. As shown in supplementary Fig. S3, the z-scores of each subunit chain are 
comparable with all experimentally determined chains in the current PDB. PROSA was also 
used to investigate the local model quality, by plotting average residue energy scores over 
each 40-residue fragment in each subunit (supplementary Fig. S4). The low occurrence of 
positive values indicates high model quality, with very few problematic regions.  
3.2 Prediction of linear epitope regions on the surface of TMEV GDVII VP1 
Linear B-cell epitope regions within TMEV GDVII VP1 were predicted using the webservers 
ElliPro and BepiPred. ElliPro incorporates the Thornton method (Thornton et al., 1986) for 
the prediction of epitopes on the surface of a protein structure. As shown in Fig. 2A, ElliPro 
identified major epitopes at both the N and C-termini of modelled GDVII VP1. Epitopes 
were also predicted in the central region of the protein ranging from residues 140-220. To 
substantiate these ElliPro results, the BepiPred method was applied. BepiPred is a sequence 
based method, and uses a combination of hidden Markov Models and propensity scales. The 
results (Fig. 2B) predict five epitopes in the N-terminal region with three major epitopes 
spanning the amino acids VP1 (1-18), VP1 (47-59) and VP1 (74-90). A comparative analysis 
of the ElliPro and BepiPred predictions indicated five overlapping epitope regions within the 
first 100 amino acids of the protein (supplementary table S4), while the predictions directly 
contradicted in the central residues 170-200.  
Successful immunisation requires a substantial amount of soluble protein. Therefore, we 
aimed to express a VP1 region which was likely to be soluble as well as contain linear 
epitopes to elicit an immune response. A Kyte-Doolittle plot was used to assess the 
hydrophobicity across the GDVII VP1 protein. The results indicated a hydrophobic region 
spanning the residues 120-200, as opposed to several hydrophilic peaks located in the N-
terminal region (supplementary Fig. S5). Subsequent to this observation it was hypothesised 
that the N-terminal region of VP1 had a higher likelihood of being soluble than the central 
region of the protein. 
To structurally determine the surface accessibility of the overlapping epitopes in the N-
terminal region ranging from the residues 1-105, the predicted epitopes were mapped into the 
GDVII protomer in PyMOL (Fig. 3). The structural mapping indicated that all five epitopes 
are surface exposed in the protomer complex. The protomers assemble to form pentamer 
structures and later a full capsid, where the protomer has an external and internal capsid face.  
The horizontal rotation of the protomer showed in Figs. 3A and 3B, revealed the location of 3 
epitopes which reside externally and 2 epitopes on the internal face of the complex. 
Antibodies have been reported to also bind to the internal region of VP1 exposed during 
capsid breathing in Poliovirus 1 (Lin et al., 2012) and Parechovirus 1 (Kalynych et al., 2015). 
It was therefore hypothesised that generating polyclonal antibodies against a peptide 
spanning the full VP1 (1-105) region, would result in antibodies which would recognise the 
VP1 protein and in the assembled capsid. After the consideration of primer design, the region 
VP1 (1-112) was selected for expression, purification and antibody production.  
3.3 VP1 (1–112) is expressed as a soluble peptide in the presence of sarcosyl 
JM109 E. coli cultures harbouring pCRTVP1 and pQE-80L were grown to mid-log phase and 
induced with 1mM  IPTG for 4 hours, in order to analyse the expression of VP1 (1-112). An 
over expressed peptide of approximately 19 kDa was detectable at 1 hour post-induction, and 
increased in intensity with time reaching a maximum at around 3 hours (Fig. 4A). The 
peptide was not evident at the start of the induction or in lysate from cells harbouring the 
empty pQE-80L vector (Fig. 4A). Western blot using anti-His6 antibodies confirmed that the 
peptide was recombinant VP1 (1-112) (Fig. 4B).  
To produce enough recombinant VP1 (1-112) for immunisation purposes, an 80ml culture of 
transformed E.coli JM109 cells, harbouring pCRTVP1 was induced with IPTG for 4 hours,  
divided into 2x40ml and cells were harvested through centrifugation. The cells were 
resuspended in 1XLEW [50 mM Na2PO4, 300 mM NaCl, (pH 8.0)] buffer supplemented with 
30 mM imidazole and sonicated either in the absence or in the presence of 7.5% sarcosyl 
(data not shown). In the absence of sarcosyl, a significant amount of the peptide was found in 
the pellet. The addition of 7.5% sarcosyl increased the solubility of the peptide, with only 
small traces in the pellet and the majority of the peptide present in the soluble fraction (data 
not shown).  
3.4 Anti-TMEV VP1 (1-112) antibodies recognise full length VP1 in infected cell lysates 
To determine whether the resultant polyclonal anti-VP1 (1-112) antibodies could detect 
virally expressed VP1, BHK-21 cells were infected or mock-infected with TMEV for a 
period of 5, 8 and 24 hours. Total cell lysates were then analysed together with bacterially 
expressed VP1 (1-112) lysate by Western blot. A peptide of approximately 19 kDA 
representing VP1 (1-112) was detected in the bacterial lysate as expected (Fig. 5).  The anti- 
TMEV VP1 (1-112) antibodies successfully detected a virally expressed protein of 
approximately 37 kDa in TMEV infected cell lysates and signal increased in intensity with 
time post infection (Fig. 5). No protein bands were detected in mock-infected cell lysate, 
indicating that the signal detected in infected lysates was a result of TMEV infection. Pre-
immune serum was not able to detect the 19 kDa or 37 kDa bands in bacterial or infected cell 
lysates (data not shown). 
3.5 TMEV VP1 distributes in the cytoplasm and perinuclear region but not in the nucleus of 
infected cells 
To examine the distribution of VP1 in TMEV-infected cells, BHK-21 cells were infected or 
mock-infected with TMEV, fixed with paraformaldehyde at 5 hpi, and immunostained with 
anti-TMEV VP1 and 2C antibodies.  No signal was observed in either mock-infected cells 
(Fig. 6A panel a) or in infected cells stained with secondary antibodies alone (Fig. 6A panel 
b). To confirm that cells were TMEV infected and to compare VP1 distribution, previously 
generated anti-TMEV 2C antibodies (Jauka et al., 2010) were used (Fig. 6A panel c). The 2C 
signal appears dominant in the perinuclear region as previously reported (Jauka et al., 2010; 
Mutsvunguma et al., 2011). Following the optimisation of anti-TMEV VP1 (1-112) 
antibodies using different dilutions (data not shown), the VP1 signal was diffusely 
cytoplasmic and in the perinuclear region but absent from the nucleus of infected cells at 5 
hpi (Fig. 6A panel d). Importantly, all infected cells observed at this time point in three 
separate experiments showed the same cytoplasmic distribution pattern for VP1. Following 
analysis of the TMEV VP1 sequence, no typical NLS was observed. Likewise, the programs 
used did not detect a NLS in the VP1 sequences of CVB3, EV71 or FMDV. A multiple 
alignment of C-terminal VP1 regions of TMEV, FMDV, EV71 and CVB3 shown in Fig. 6B 
showed that the basic histidine residue at position 220, suggested to be responsible for 
nuclear localisation of CBV3, was replaced by threonine in EV71 VP1, glycine in TMEV 
VP1 and valine in FMDV.  
3.6 TMEV VP1 colocalises with Hsp90 at 5 hours post infection  
To examine the sub-cellular distribution of VP1 in relation to Hsp90 during infection, cells 
grown on coverslips were infected with TMEV, fixed with paraformaldehyde at 5 hpi and co-
stained with Hsp90 and anti-TMEV VP1 (1-112) antibodies. No signal for VP1 was observed 
in mock-infected cells probed with anti-TMEV VP1 antibodies (Fig. 7A). The distribution of 
Hsp90 in mock-infected cells was diffuse and cytoplasmic (Fig. 7A panel a) but changed at 5 
hpi becoming more intense in the perinuclear region (Fig. 7B panel d). Interestingly, the 
signals for TMEV VP1 and Hsp90 colocalised extensively in the cytoplasm and perinuclear 
region (displayed by white pixels in Fig. 7B panel f). Moreover, the frequency scatter plots 
indicate a high degree of colocalisation between the two signals (Fig. 7B panel g). The profile 
taken along a section of the TMEV infected cell (Fig. 7 panel h) shows that the green (VP1) 
and red (Hsp90) signal intensities correlate with each other throughout the cell with increased 
intensity in the perinuclear region compared to the cytoplasm. In comparison, Hsp90 and 2C 
signal was largely perinuclear and colocalised in this region (Fig. 7C panels i-k). The 
frequency scatterplot confirmed colocalisation (Fig. 7C panel l) and the profile clearly shows 
that red (Hsp90) and green (2C) signal intensities were less correlated in the cytoplasm than 
in the case of VP1, and increased asymmetrically in the perinuclear region (Fig. 7 panel m). 
The above analysis was performed on five randomly selected cells co-stained with anti-
VP1/anti-2C and Hsp90 antibodies.   
 
4. Discussion 
The primary aim of this study was to generate antibodies against the TMEV GDVII VP1 
protein subunit and test their specificity in detecting VP1 in infected cells by Western blotting 
and indirect immunofluorescence. To date, very few studies describe the localisation of 
picornavirus capsid subunits in cells at early stages of virus assembly which remains a poorly 
understood process in the virus life cycle. There is substantial evidence to suggest that 
picornavirus replication and assembly take place on the surface of specialised membrane 
vesicles and that the viral proteins associate with these membranes (Bienz et al., 1983; Egger 
et al., 2002; Jackson et al., 2005; Schwartz et al., 2004) thereby complicating their 
solubilisation and purification in a heterologous system for downstream applications. Indeed, 
previous attempts to solubilise and purify the full-length TMEV VP1 protein were 
unsuccessful. To address this problem, a bioinformatics approach was used to map a region 
on VP1 predicted to contain surface-exposed linear B-cell epitopes, and which could be 
purified in a soluble form for immunisation purposes. Because VP1 exists as part of a 
protomer complex within the viral capsid, homology modelling was used to generate a 3D 
structure of the TMEV protomer complex to accurately predict and assess the surface 
accessibility of linear epitopes on the protein. Furthermore, since VP1 is an antigenic 
determinant of the capsid, it was reasonable to assume that antibodies generated against an 
immunogenic VP1 peptide would also recognise the full-length protein as well as viral 
capsids in infected cells. Following a bioinformatics analysis of VP1, the N-terminal region 
(amino acids 1-112) was predicted to contain surface linear B-cell epitopes at amino acid 
positions 1-18, 24-30, 50-56, 78-88, 98-105, and was selected for bacterial expression and 
purification. The antibodies were able to detect the bacterially expressed VP1 peptide (1-112) 
as expected, but were also specific in detecting full length VP1 protein in TMEV-infected 
cells lysates with no contaminating proteins. Because lysates were not fractionated in these 
experiments, it cannot be concluded that TMEV VP1 is present predominantly in a 
membrane-associated or soluble form. It is surprising that the P1 precursor protein was not 
detected in infected cell lysates using anti-TMEV VP1 antibodies. This observation will be 
further investigated and if found to be valid, indicates that these antibodies are an extremely 
useful tool in investigating the localisation and interactions of VP1 with host components 
during virus assembly. 
To investigate the localisation of VP1 in TMEV-infected BHK-21 cells, the next experiments 
examined the specificity of the anti-TMEV VP1 (1-112) antibodies in detecting VP1 in cells 
by indirect immunofluorescence and confocal microscopy at 5 hpi. A clear signal was 
detected in infected cells but not in mock infected cells indicating that the antibodies were 
specific for VP1 at an optimal dilution of 1:20 000. The distribution of TMEV VP1 at 5 hpi 
was diffusely cytoplasmic with increased signal intensity in the perinuclear region. This 
pattern was observed in over 100 cells (data not shown). Cytoplasmic VP1 may represent 
soluble protein at this stage of infection and preliminary experiments using anti-VP1 
antibodies indicate that VP1 is present in both membrane and supernatant fractions (data not 
shown). Interestingly, TMEV VP1 was not observed in the nucleus at 5 hpi. The capsid 
proteins of several RNA viruses such as West Nile Virus (WNV) (Bhuvanakantham et al., 
2010), porcine reproductive and respiratory syndrome virus (PRRSV) (Pei et al., 2009), 
Dengue virus (Colpitts et al., 2011) and the picornavirus CVB3 (Wang et al., 2012), have 
been reported to translocate to the nucleus during infection where they interfere with essential 
nuclear functions. Proteins targeted to the nucleus in cells typically possess a C-terminal 
nuclear localisation signal (NLS) consisting of a stretch of basic amino acids that is bound by 
nuclear import receptors (McLane and Corbett, 2009). For the identification of possible 
NLS’s, the full length VP1 sequences of TMEV, FMDV, CVB3 and EV71 were analysed in 
silico by NucPred and SeqNLS. Both programs indicated the absence of a typical NLS in all 
four viral proteins.  However, previous analysis of the CVB3 VP1 sequence showed that, 
although the protein did not display a typical NLS, a C-terminal histidine residue at position 
220 (H220) was a critical determinant required for active translocation to the nucleus (Wang 
et al., 2012). To investigate whether this residue is present in TMEV and other related 
viruses, a multiple sequence alignment between VP1 C-terminal sequences of several 
picornaviruses was performed. The H220 in CVB3 was substituted for threonine in EV71 
VP1 which has been shown to distribute in the cytoplasm of infected cells (Liu et al., 2013; 
Wang et al., 2012). The lack of a typical NLS and observation that H220 is replaced by 
glycine in TMEV VP1 provides an explanation for the similar cytoplasmic distributions of 
EV71 and TMEV VP1 proteins. Similarly in FMDV VP1, the H220 residue is replaced by 
valine. Interestingly, the distribution of TMEV VP1 at 5 hpi was not unlike that of FMDV 
during late infection where VP1 localised predominantly to the perinuclear region of FMDV 
infected cells and colocalised with the replication protein 2C (Knox et al., 2005). 
Hsp90 has vital functions in the cell including protein folding and trafficking, maintenance of 
protein stability and regulation of cell growth and differentiation (Passinen et al., 2001; 
Picard, 2004; Pratt and Toft, 2013; Zhang et al., 2013). Hsp90 is upregulated under 
conditions of stress, including viral infection, and is required for the replication and capsid 
assembly of many viruses, including picornaviruses such as PV and HRV (Geller et al., 
2012). Therefore the next experiments investigated the localisation of VP1 relative to Hsp90 
during TMEV infection. In 5-hour infected cells, the Hsp90 signal was greater in intensity 
compared to mock-infected cells and became concentrated in the perinuclear region where it 
colocalised with VP1. The staining pattern for Hsp90 at 5 hpi observed in this study concurs 
with that reported by Mutsvunguma et al. (2011) where the distribution of Hsp90 was time 
dependent, moving from a diffuse cytoplasmic staining pattern during early infection and 
becoming concentrated in the perinuclear region at later time points.  
Interestingly, VP1 and Hsp90 showed good signal correlation in infected cells where 
colocalisation occurred in the cytoplasm and perinuclear region of infected cells. In 
comparison, Hsp90 and 2C signals were less correlated and colocalisation was only apparent 
in the juxtanuclear region. A five hour time point may be considered relatively early during 
TMEV infection as cytopathic effect is only observed from about 7 hpi. The data showing 
that Hsp90 and VP1 colocalise suggest that Hsp90 is required during the early stages of 
TMEV capsid assembly. These results support existing evidence that Hsp90 is involved in the 
picornavirus capsid assembly but may not be directly involved with virus replication (Geller 
et al., 2007).  
In conclusion, this is the first study to report the distribution of TMEV VP1 in infected cells 
by Western blot and indirect immunofluorescence. Significantly, VP1 signal distribution was 
found to be cytoplasmic with greater signal intensity in the perinuclear region. This coupled 
with its absence from the nucleus and the lack of a typical NLS indicate that TMEV VP1 
behaves in a similar manner to that of picornaviruses such as FMDV and Enterovirus 71. 
Overlap between VP1 and Hsp90 distribution supports the previous observation that Hsp90 
plays an important role for this chaperone in the TMEV life cycle (Mutsvunguma et al., 
2011). The generation of TMEV VP1 specific polyclonal antibodies and their optimisation by 
Western blot and indirect immunofluorescence is an important milestone that has provided 
the tool and methodologies necessary for future studies investigating interactions between 
this capsid subunit and host cell factors to better understand not only the process of capsid 
assembly but also the mechanisms involved in the early stages of picornavirus entry. 
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Figure Captions 
Fig 1. Assembly of Picornavirus particles. Hsp90 mediates a conformational change in the 
P1 precursor, allowing cleavage by the 3CD and 3C proteases. Resulting VP0, VP1 and VP3 
capsid proteins form the capsomer, of which 5 combine to produce the pentamer. 12 
pentamers then associate around the mRNA genome to generate the provirion. VP0 is then 
cleaved yielding the outer facing VP2 capsid protein and the internally oriented VP4 protein, 
maturing the newly formed virion. Alternatively 12 pentamers can assemble without 
inclusion of the mRNA genome to yield empty 80S procapsids. Purified pentamers are able 
to assemble into empty procapsids in a cell free test tube environment through “self-
assembly”, indicating that assembly from pentamer to capsid maturation is based on protein-
protein interactions (Li et al., 2012). However the stages from P1 precursor cleavage to 
pentamer formation remain enigmatic, and seem to require both viral and host cell factors. 
Adapted from Jiang et al. (2014). 
Fig 2. Predicted linear B-cell epitopes within TMEV GDVII VP1 protein. A) An ElliPro 
plot of predicted linear B-cell epitopes based on the homology model of the GDVII protomer. 
B) BepiPred plot of predicted linear B-cell epitope regions based on the primary amino acid 
sequence of GDVII VP1. Predicted epitopes are indicated by positive peaks. The peptide 
region selected for antigen production is indicated by the black dashed arrow: VP1 (1-112). 
Fig 3. Homology model of the TMEV GDVII protomer complex showing predicted VP1 
linear B-cell epitopes. The model based on two homologous viral protomer structures of 
Theiler’s Virus (1TME) and Enterovirus D68 (4WM8), was generated using MODELLER. 
The model has been coloured by subunit: green - VP1; cyan - VP2; pink - VP3; yellow - 
VP4; orange - amino acid regions predicted to map to linear B-cell epitopes as predicted by 
both ElliPro and BepiPred. A) PyMOL generated image showing epitope regions VP1: 50-
56; 78-88; 98-105. B) Horizontal rotation of the 3D structure showing epitope regions VP1: 
1-18 and 24-30. 
Fig 4. Expression and analysis of TMEV VP1 (1-112) protein. (A) SDS-PAGE analysis of 
an induction study of VP1 (1-112) over time. The protein represents total cell extract over 
time after induction with 1 mM IPTG. MW (molecular weight marker in kDa). Cells were 
transformed with pCRTVP1 and induced hourly for 4 hours using IPTG. Cells were 
transformed with pQE80-L and induced for 4 hours using IPTG (negative control). (B) 
Expression of His-tagged TMEV VP1 (1-112) confirmed by Western blot using anti-His6 
antibodies. 
Fig 5. Detection of recombinant VP1 (1-112) and full-length VP1. Western blot of 
bacterially expressed lysate and TMEV infected BHK-21 lysates at various times post-
infection, using anti-TMEV VP1 (1-112) peptide antibodies. MW (molecular weight marker 
in kDa).  
Fig 6. A) Distribution of TMEV VP1 in 5-hour infected BHK-21 cells. Cells were mock 
infected (panel a) or infected with TMEV (panels b, c and d), fixed with paraformaldehyde at 
5 hpi and stained with anti-TMEV VP1 (1-112) (panels a and d), or anti-TMEV 2C (panel c) 
antibodies. Primary antibodies were detected with species-specific Alexa Fluor 488-
conjugated secondary antibodies. Cells in panel b were stained with Alexa Fluor 488-
conjugated secondary antibodies only. Scale bars = 20 μm. B) Multiple sequence alignment 
of the C-terminus of VP1 proteins of CVB3, EV71, TMEV and FMDV. Full length 
protein sequences were retrieved from GenBank and aligned using Promals3D. The aligned 
C-terminus region was subsequently visualised in Jalview. The arrow indicates the site of 
substitution from basic histidine in CVB3 to the neutral residues threonine, glycine and valine 
in EV71, TMEV and FMDV respectively.  
Fig 7. Distribution of TMEV VP1 and 2C in relation to Hsp90. Cells were either mock 
infected (A) or infected with TMEV (B and C), paraformaldehyde fixed at 5 hpi, and co-
stained with antibodies against TMEV VP1 (A and B) or 2C (C), as well as antibodies against 
Hsp90 α/β. Primary antibodies were detected with species-specific Alexa-Fluor 488 or Alexa-
Fluor 546-conjugated secondary antibodies respectively. Scale bars = 20 μm. Merged Hsp90 
and TMEV signals are displayed in the form of colocalisation maps (panels c, f and k), where 
colocalised pixels are shown in white. Signal intensity profiles for green, red, and blue 
(DAPI) channels along a section of the TMEV infected cells are depicted in panels h and m. 
Frequency scatter plots of the intensity registered in the red and green channels of infected 
cells indicate the degree of colocalisation between signals for Hsp90 and TMEV (panels g 
and l). Hsp90 signal is always shown on the x axis, whereas the y axis corresponds to the 
intensity of the TMEV signal.  
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